Cognitive functions in methamphetamine induced psychosis compared to schizophrenia and normal subjects

Iranian Journal of Psychiatry

Volumn 9, Issue 3, 2014, Pages 152-157

  Ezzatpanah, Zahra ^a   Shariat, Seyed Vahid ^a,b   Tehrani doost, Mehdi ^a,c  

^a Institute for Cognitive Science Studies   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Attention; Executive function; Memory; Methamphetamine; Psychotic disorders; Schizophrenia

Indexed keywords

METHAMPHETAMINE;

ADULT; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING; LEARNING AND MEMORY TEST; MAJOR CLINICAL STUDY; MALE; MEMORY; POST HOC ANALYSIS; PSYCHOSIS; SCHIZOPHRENIA; STROOP TEST; VISION; VISUAL SEARCH AND ATTENTION TEST; WECHSLER MEMORY SCALE; WISCONSIN CARD SORTING TEST;

EID: 84906965529     PISSN: 17354587     EISSN: 20082215     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Shariat SV, Elahi A. Symptoms and course of psychosis after methamphetamine abuse: One year follow up of a case. Prim Care Companion J Clin Psychiatry 2010; 12:e1-e2.
2. Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine induced psychosis. J Ment Health 2013; 22: 341-349.
3. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17: 275-297.
4. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004 30: 6028-6036.
5. Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol 2007; 17: 46-52.
6. Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003; 15: 215-220.
7. Rendell PG, Mazur M, Henry JD. Prospective memory impairment in former users of methamphetamine. Psychopharmacology (Berl) 2009; 203: 609-616.
8. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13: 141-154.
9. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 15: 29-39.
10. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998; 24: 425-435.
11. Heinrichs RW, Zakzanis KK. Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence. Neuropsychology 1998; 12: 426-445.
12. Harvey P, Bowie C, Friedman J. Cognition in schizophrenia. Curr Psychiatry Rep 2001; 3: 423-428.
13. Jacobs E, Fujii D, Schiffman J, Bello I. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cogn Behav Neurol 2008; 21: 98-103.
14. Berg EA. A simple objective technique for measuring flexibility in thinking. J Gen Psychol 1948; 39: 15-22.
15. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 28: 643-662.
16. Trenerry MR, Crosson B, DeBoe J, Leber WR. Visual Search and Attention Test. Odessa, Florida: Psychological Assessment Resources, Inc.; 1990.
17. Filoteo JV, Williams BJ, Rilling LM, Roberts JV. Performance of Parkinson's disease patients on the Visual Search and Attention Test: impairment in single-feature but not dual-feature visual search. Arch Clin Neuropsychol 1997; 12: 621-634.
18. Wechsler D. A Standardized Memory Scale for Clinical Use. J Psychol 1945 2012/06/16; 19: 87-95.
19. Quinton MS, Yamamoto BK. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006; 8: 337-347.
20. Salo R, Nordahl TE, Galloway GP, Moore CD, Waters C, Leamon MH. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J Subst Abuse Treat 2009; 37: 292-197.
21. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 2002; 26:53-63.
22. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206-1214.
23. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-382.
24. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with (11C) WIN-35,428. J Neurosci 1998; 18: 8417-8422.
25. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160: 1699-1701.
26. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 2000; 28:1344-1349.
27. Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002; 114: 65-79.
28. Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 1998; 30: 433-45.